Mesenchymal stem cells (MSCs)-based therapy for perianal fistulizing Crohn’s disease (pfCD) has been extensively studies in the past decade. Its efficacy and safety had been preliminarily confirmed in some phase 2 or phase 3 clinical trials. This meta-analysis is performed to evaluate the efficacy and safety of MSCs-based therapy for pfCD.
Methods
Electronic databases (Pubmed, Cochrane Library, Embase) were searched for studies that reported the efficacy and safety of MSCs. And RevMan were used to assess the efficacy and safety.
Results
After screening, 5 randomized controlled trials (RCTs) were included in this meta-analysis. RevMan 5.4 for meta-analysis showed that: [Efficacy] Patients had definite remission after MSCs treatment, with an odds ratio (OR) of 2.06 (P < .0001, 95%CI 1.46, 2.89) vs controls. [Safety] The incidence of the most frequently reported TEAEs (treatment-emergent adverse events, TEAEs), perianal abscess and proctalgia, did not significantly increase due to the use of MSCs, with an OR of 1.07 in perianal abscess (P = .87, 95%CI 0.67, 1.72) vs controls, and an OR of 1.10 in proctalgia (P = .47, 95%CI 0.63, 1.92) vs controls.
Conclusions
MSCs seem to be an effective and safe therapy for pfCD. MSCs based therapy has the potential to be used in combination with traditional therapies.
SchwartzDALoftusEVJr.TremaineWJ, et al.The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122(4):875-880.
2.
DomènechEHinojosaJNosP, et al.Clinical evolution of luminal and perianal Crohn’s disease after inducing remission with infliximab: How long should patients be treated?Aliment Pharmacol Ther. 2005;22(11-12):1107-1113.
3.
JiangXXZhangYLiuB, et al.Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005;105(10):4120-4126.
4.
BeythSBorovskyZMevorachD, et al.Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005;105(5):2214-2219.
5.
MeliefSMGeutskensSBFibbeWERoelofsH. Multipotent stromal cells skew monocytes towards an anti-inflammatory function: The link with key immunoregulatory molecules. Haematologica. 2013;98(9):e121-e122.
HerreraMBBussolatiBBrunoSFonsatoVRomanazziGMCamussiG. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med. 2004;14(6):1035-1041.
9.
MoherDLiberatiATetzlaffJAltmanDGPRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed). 2009;339:b2535.
10.
PanésJGarcía-OlmoDVan AsscheG, et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: A phase 3 randomised, double-blind controlled trial. Lancet (London, England). 2016;388(10051):1281-1290.
11.
MolendijkIBonsingBARoelofsH, et al.allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with crohn’s disease. Gastroenterology. 2015;149(4):918-927.
12.
PanésJGarcía-OlmoDVan AsscheG, et al.Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with crohn’s disease. Gastroenterology. 2018;154(5):1334-1342.
13.
Garcia-OlmoDGilaberteIBinekM, et al.Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel (mesenchymal stem cell treatment) in patients with perianal fistulizing crohn’s disease: ADMIRE-CD phase 3 randomized controlled trial. Dis Colon Rectum. 2022;65(5):713-720.
14.
PanésJBoumaGFerranteM, et al.INSPECT: A retrospective study to evaluate long-term effectiveness and safety of darvadstrocel in patients with perianal fistulizing crohn’s disease treated in the ADMIRE-CD trial. Inflamm Bowel Dis. 2022;28(11):1737-1745.
15.
Lennard-JonesJE. Toward optimal use of corticosteroids in ulcerative colitis and Crohn’s disease. Gut. 1983;24(3):177-181.
16.
GomollónFDignassAAnneseV, et al.3rd European evidence-based consensus on the diagnosis and management of crohn’s disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis. 2017;11(1):3-25.
17.
HinterleitnerTAPetritschWAichbichlerBFickertPRannerGKrejsGJ. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease. Z Gastroenterol. 1997;35(8):603-608.
18.
ThiaKTMahadevanUFeaganBG, et al.Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: A randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009;15(1):17-24.
19.
SandbornWJPresentDHIsaacsKL, et al.Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: A randomized, placebo-controlled trial. Gastroenterology. 2003;125(2):380-388.
20.
PresentDHRutgeertsPTarganS, et al.Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398-1405.
21.
García-OlmoDGarcía-ArranzMHerrerosDPascualIPeiroCRodríguez-MontesJA. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48(7):1416-1423.
KotzePGShenBLightnerA, et al.Modern management of perianal fistulas in Crohn’s disease: Future directions. Gut. 2018;67(6):1181-1194.
24.
DietzABDozoisEJFletcherJG, et al.Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with crohn’s disease. Gastroenterology. 2017;153(1):59-62.
25.
ParkKJRyooSBKimJS, et al.Allogeneic adipose-derived stem cells for the treatment of perianal fistula in Crohn’s disease: A pilot clinical trial. Colorectal Dis. 2016;18(5):468-476.
26.
ChengFHuangZLiZ. Mesenchymal stem-cell therapy for perianal fistulas in Crohn’s disease: A systematic review and meta-analysis. Tech Coloproctol. 2019;23(7):613-623.
27.
LeeMJParkerCETaylorSR, et al.Efficacy of medical therapies for fistulizing crohn's disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(12):1879-1892.
